APLS vs. BPMC, BBIO, OGN, IONS, PRGO, NUVL, CYTK, ALPN, ELAN, and ALKS
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Nuvalent (NUVL), Cytokinetics (CYTK), Alpine Immune Sciences (ALPN), Elanco Animal Health (ELAN), and Alkermes (ALKS). These companies are all part of the "pharmaceutical preparations" industry.
Blueprint Medicines (NASDAQ:BPMC) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk.
In the previous week, Blueprint Medicines had 36 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 59 mentions for Blueprint Medicines and 23 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.55 beat Blueprint Medicines' score of 0.24 indicating that Blueprint Medicines is being referred to more favorably in the media.
Blueprint Medicines has a net margin of -102.15% compared to Blueprint Medicines' net margin of -133.34%. Blueprint Medicines' return on equity of -178.60% beat Apellis Pharmaceuticals' return on equity.
Blueprint Medicines has higher earnings, but lower revenue than Apellis Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Blueprint Medicines presently has a consensus target price of $100.31, indicating a potential downside of 7.78%. Apellis Pharmaceuticals has a consensus target price of $76.67, indicating a potential upside of 81.25%. Given Blueprint Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Blueprint Medicines.
Blueprint Medicines received 201 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. Likewise, 67.80% of users gave Blueprint Medicines an outperform vote while only 67.45% of users gave Apellis Pharmaceuticals an outperform vote.
96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 3.9% of Blueprint Medicines shares are owned by insiders. Comparatively, 7.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Blueprint Medicines has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
Summary
Apellis Pharmaceuticals beats Blueprint Medicines on 10 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
